Revenues for the first half of 2022 and update on AB Science’s activities
30/09/2022 – AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19
14/09/2022 – AB Science announced continuation of the Phase 2 study evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS
24/08/2022 – AB Science today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS)
Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and Allergy
07/06/2022 – AB Science today announced the publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids (OCS) in the peer-reviewed Journal of Asthma and Allergy
AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS
26/05/2022 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
Annual financial results as of 31 December, 2021
29/04/2022 – AB Science reports its revenues for the year 2021 and provides an update on its activities
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19
28/04/2022 – AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)
29/03/2022 – AB Science acknowledges the decision of the Enforcement Committee of the French market regulator (AMF), which has cleared its Chief Executive Officer, Alain Moussy, in a decision concerning possible insider trading.
Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indications
28/02/2022 – Presentation of the webcast held on February 28, 2022 on masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indications
Financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrants
28/02/2022 – AB Science announces today that it reached an agreement with a historical investor on a financing of USD 8.5 million through the issuance of bonds convertible into new ordinary shares with attached warrants